Search and apply for every grant in existence.

Summary: The fiscal year 2026 (FY26) Multiple Sclerosis Research Program (MSRP) Exploration – Hypothesis Development Award (EHDA) supports the initial exploration of innovative, high-risk, high-gain, and potentially groundbreaking concepts in the Multiple Sclerosis (MS) research field. The studies supported by this award mechanism are expected to lay the groundwork for future avenues of scientific investigation. All applications must address at least one of the FY26 MSRP EHDA focus areas. The proposed research project should include a well-formulated, testable hypothesis based on strong scientific rationale and study design. The presentation of preliminary and/or published data is not required.Distinctive Features: This funding mechanism includes two options: Established Investigator and New Investigator. The New Investigator option supports applicants early in their faculty appointments. Funding Opportunity Number: HT942526MSRPEHDA. Assistance Listing: 12.420. Funding Instrument: G. Category: ST. Award Amount: $2M total program funding.

The National Aeronautics and Space Administration (NASA) Headquarters has released the solicitation Early Stage Innovations for In Situ Resource Utilization (ESI26-ISRU), as an appendix to the Research and Technology Mission Directorate (RTMD) umbrella NASA Research Announcement (NRA) titled "Space Technology Research, Development, Demonstration, and Infusion 2026 (SpaceTech REDDI 2026).”. The solicitation is available by opening the NSPIRES homepage at https://nspires.nasaprs.com/, selecting “Open” under "Solicitations," and searching "Early Stage Innovations (ESI26)” under Keywords, or directly via https://solicitation.nasaprs.com/NNH26ZTR001N-26ESI_B7. Through ESI, Space Technology Research Grants (STRG) Program within RTMD solicits proposals from U.S. institutions of higher education (IHEs) for innovative, early-stage space technology research of high priority to NASA. Proposals are sought on specific space technologies that are currently at low Technology Readiness Levels (TRLs). The solicitation exclusively seeks proposals that are primarily responsive to civil-space needs and use cases and not terrestrial and/or non-civil-space applications. The solicitation exclusively seeks proposals that are responsive to the following topic: Lunar In Situ Resource Utilization Water Purification. Only U.S. IHEs are eligible to submit proposals to this Appendix. The Principal Investigator (PI) must be either a tenured faculty member or an untenured faculty member on the tenure track from the proposing IHE. Teaming and collaboration are permitted, subject to the restrictions described in the solicitation. The financial and programmatic support for ESI comes from the STRG Program within RTMD. Awards are planned to start in June 2027. NASA plans to make approximately 3 awards as a result of this ESI solicitation, subject to the receipt of meritorious proposals and the availability of funds. The actual number of awards will depend on the quality of the proposals received; NASA reserves the right to make no awards under this solicitation. All proposals must be submitted electronically through NSPIRES by an authorized organizational representative. Proposals are being solicited via a two-step process where preliminary proposals are mandatory and only those invited may submit a full proposal. Mandatory preliminary proposals are due on or before August 13, 2026, 5 pm Eastern, and the target deadline for invited full proposals is December 16, 2026, 5 pm Eastern. Detailed submission instructions and due dates are provided in the solicitation. Potential proposers and their proposing organizations are urged to familiarize themselves with the submission system, ensure they are registered in NSPIRES, and submit the required proposal materials well in advance of the deadline. Technical and programmatic comments and questions may be addressed by email to the Space Technology Research Grants Program Executive at hq-esi-call@mail.nasa.gov. Responses to inquiries will be answered by email and may also be included in the Frequently Asked Questions (FAQ) documents located on the NSPIRES page associated with the solicitation; anonymity of persons/institutions who submit questions will be preserved. Funding Opportunity Number: NNH26ZTR001N-26ESI-B7. Assistance Listing: 43.012. Funding Instrument: G. Category: ST. Award Amount: Up to $1.5M per award.

Summary: The fiscal year 2026 (FY26) Multiple Sclerosis Research Program (MSRP) Clinical Trial Award (CTA) supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of multiple sclerosis. All applications must address at least one of the FY26 MSRP CTA focus areas. Clinical trials may evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance and/or emerging approaches and technologies.Distinctive Features: The FY26 CTA offers two funding levels. The following are generalized descriptions of the scope of research appropriate for each funding level:• Funding Level 1 (CTA-FL1) supports small-scale, proof-of-principle clinical trials (e.g., pilot, first-in-human, phase 0) to demonstrate feasibility or inform the design of more advanced trials, or other clinical trials that are appropriate for this funding level. Preliminary data relevant to the proposed clinical trial are required.• Funding Level 2 (CTA-FL2) supports larger-scale clinical trials at phase 1 or phase 2 that seek to show preliminary evidence of safety or efficacy (i.e., benefit of clinical or paraclinical outcomes) in relevant patient populations. Clear description and justification should be provided, which could include, but is not limited to, the intervention type, trial duration, sample size, outcome measures, assessment tools and frequency of assessment. Preliminary data relevant to the proposed clinical trial in MS populations are required.For the purposes of this funding opportunity, Regulatory Agency refers to the U.S. Food and Drug Administration (FDA) or any relevant international regulatory agency unless otherwise noted. Funding Opportunity Number: HT942526MSRPCTA. Assistance Listing: 12.420. Funding Instrument: G. Category: ST. Award Amount: $4M total program funding.